Ann Arbor, MI – According to filings with the U.S. Securities and Exchange Commission, ONL Therapeutics is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Esposito played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ONL Therapeutics

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserving sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and a completely unaddressed medical need.

To learn more about ONL Therapeutics, visit http://www.onltherapeutics.com/

Contact:
David Esposito, Chief Executive Officer
734-926-5530
desposito@onltherapeutics.com
https://www.linkedin.com/in/davidesposito2/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved